NCT06604767 - Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

March 5, 2026

Study Completion Date

March 5, 2026

Conditions

Respiratory Syncytial Virus InfectionMetapneumovirus InfectionParainfluenzae Virus Infection

Interventions

BIOLOGICAL

parainfluenza virus type 3 vaccine (PIV3)

Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

BIOLOGICAL

RSV/hMPV/PIV3 vaccine

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

BIOLOGICAL

RSV/hMPV vaccine

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

BIOLOGICAL

RSV vaccine 1

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

BIOLOGICAL

RSV vaccine 2

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Trial Locations (8)

2019

Investigational Site Number : 0360001, Botany

2100

Investigational Site Number : 0360009, Brookvale

2148

Investigational Site Number : 0360006, Blacktown

2228

Investigational Site Number : 0360004, Miranda

2259

Investigational Site Number : 0360005, Kanwal

3124

Investigational Site Number : 0360002, Camberwell

3153

Investigational Site Number : 0360003, Bayswater

4006

Investigational Site Number : 0360008, Herston

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY